Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.
Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW; Mood Disorders Precision Medicine Consortium (MDPMC). Ahmed AT, et al. J Affect Disord. 2018 Oct 1;238:1-7. doi: 10.1016/j.jad.2018.05.005. Epub 2018 May 26. J Affect Disord. 2018. PMID: 29807322 Free PMC article.
Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT, Biernacka JM, Jenkins G, Rush AJ, Shinozaki G, Veldic M, Kung S, Bobo WV, Hall-Flavin DK, Weinshilboum RM, Wang L, Frye MA. Ahmed AT, et al. J Affect Disord. 2019 Mar 1;246:62-68. doi: 10.1016/j.jad.2018.12.021. Epub 2018 Dec 17. J Affect Disord. 2019. PMID: 30578947 Free PMC article.
Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications.
Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Veldic M, et al. Among authors: ahmed at. Front Pharmacol. 2019 Feb 19;10:83. doi: 10.3389/fphar.2019.00083. eCollection 2019. Front Pharmacol. 2019. PMID: 30837869 Free PMC article.
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Zhu H, Mahmoudiandehkordi S, Neavin D, Louie G, Dunlop BW, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk R. Bhattacharyya S, et al. Among authors: ahmed at. Transl Psychiatry. 2019 Jul 4;9(1):173. doi: 10.1038/s41398-019-0507-5. Transl Psychiatry. 2019. PMID: 31273200 Free PMC article. Clinical Trial.
Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.
Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Moseley MA, Thompson JW, Williams LSJ, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald WM, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, Dunlop BW, Millington DS, Rush AJ, Frye MA, Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC). Ahmed AT, et al. J Affect Disord. 2020 Mar 1;264:90-97. doi: 10.1016/j.jad.2019.11.122. Epub 2019 Nov 30. J Affect Disord. 2020. PMID: 32056779 Free PMC article.
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, Han X, Baillie RA, Arnold M, Skime MK, John-Williams LS, Moseley MA, Thompson JW, Louie G, Riva-Posse P, Craighead WE, McDonald W, Krishnan R, Rush AJ, Frye MA, Dunlop BW, Weinshilboum RM, Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC). MahmoudianDehkordi S, et al. Among authors: ahmed at. Transl Psychiatry. 2021 Mar 2;11(1):153. doi: 10.1038/s41398-020-01097-6. Transl Psychiatry. 2021. PMID: 33654056 Free PMC article.
Age-Dependent Sex Differences in the Prevalence of Selective Serotonin Reuptake Inhibitor Treatment: A Retrospective Cohort Analysis.
Sanchez-Ruiz JA, Leibman NI, Larson NB, Jenkins GD, Ahmed AT, Nunez NA, Biernacka JM, Winham SJ, Weinshilboum RM, Wang L, Frye MA, Ozerdem A. Sanchez-Ruiz JA, et al. Among authors: ahmed at. J Womens Health (Larchmt). 2023 Nov;32(11):1229-1240. doi: 10.1089/jwh.2022.0484. Epub 2023 Oct 19. J Womens Health (Larchmt). 2023. PMID: 37856151 Free PMC article.
117 results